References in periodicals archive ?
The statements in this news release regarding anticipated cost savings resulting from Avigen's decision to discontinue funding its proprietary AAV technology, Avigen's belief that its decision to focus its existing resources on traditional pharmaceuticals offers a greater potential to increase shareholder value, Avigen's expectation on making a decision soon on pursuing a transaction, Avigen's intention to build a strong neurologically-focused pipeline through a combination of internal research, acquisitions and in-licensing, and the benefits that Avigen believes it will obtain from its change in focus, are forward-looking statements that are subject to risks and uncertainties.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements regarding our intellectual property, research programs and clinical trials, our product development and our potential development platforms including AAV vectors and other statements about our plans, objectives, intentions and expectations.
Cell Genesys has demonstrated successful gene delivery using AAV vectors in multiple preclinical studies in addition to hemophilia including studies in neurologic disorders such as Parkinson's disease.
Musculo-Skeletal: Gene Expression and Immunology of Musculoskeletal Gene Therapy "Clinical Development of an AAV Vector Expressing the TNF Receptor: Fc Fusion Gene in Inflammatory Arthritis.
This pilot study used AAV to deliver the TNFR:Fc transgene to periodontal lesions in mice.
In the study, AAV vectors were used to deliver DNA sequences encoding short interfering RNAs (siRNA) by direct injection into the brains of mice with HD.
Targeted Genetics' latest patent expands the Company's AAV vector technology," said Barrie J.
The issuance of Targeted Genetics' latest patent further strengthens our leadership position in the field of AAV manufacturing," said Barrie J.
This patent covers adenovirus AAV (Ad-AAV) hybrid vectors encoding the receptor for very low density lipoprotein (VLDL).
patent #6,989,264 is titled, "Methods for generating high titer helper-free preparation of released recombinant AAV vectors.
Avigen's AAV patent portfolio now includes 18 issued and licensed patents with extensive coverage of AAV as a gene delivery vehicle and its use in various inherited and acquired disorders.
AOG" or the "Corporation") (AAV - TSX, AAV - NYSE) announced today that it has completed the previously announced plan of arrangement (the "Arrangement") involving AOG and Advantage Energy Income Fund (the "Fund"), pursuant to which, the Fund converted into the Corporation.
Medical browser ?
- Aarskog syndrome
- Aarskog, Dagfinn
- Aarskog's syndrome
- Aase, Jon Morton
- Aase's syndrome
- Aase-Smith syndrome
- Aastrom CPS
- Aastrom Replicell System
- AAUAAA sequence
- Ab amyloid
- ab initio
- Ab Initio Gene Prediction
- AB-180 PTVA
- abacavir sulfate
- Abadie sign
- Abadie sign of tabes dorsalis
- Abadie, Charles A.
- Abadie, Joseph Louis Irenee Jean
- Abadie's sign
- Abadie's sign of exophthalmic goiter
- Abadie's sign of tabes dorsalis
Full browser ?
- Aav, Evald
- AAVE accents
- Aavishkaar India Micro Venture Capital Fund